Magnesium supplements can interact with antibiotics and bone-loss drugs, reducing their effectiveness. High doses may cause diarrhea, nausea, and low blood pressure. Experts advise talking to a health care provider before use.
The FDA has accepted Ascelia Pharma's NDA for Orviglance, a manganese-based oral MRI contrast agent for liver imaging in patients with severe kidney impairment, and set a PDUFA action date of July 3, 2026.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
